Clinical Trial

Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a Phase 2, multicenter, open-label, single-arm study to evaluate the efficacy and safety of sapanisertib and serabelisib (PIKTOR) with paclitaxel in participants with advanced or recurrent endometrial cancer.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2024-06-12; most recent amendment 2025-12-22.
Status change: Not Yet Recruiting → Recruiting 2024-12-16
Trial Details
NCT Number NCT06463028
Lead Sponsor Faeth Therapeutics
Collaborators: GOG Foundation
Conditions Endometrial Cancer
Enrollment 40 participants
Start Date 2024-12-12
Primary Completion 2028-09 (estimated)
Study Completion 2029-09 (estimated)
Updated on ClinicalTrials.gov 2025-12-24